Mugawar B, Mcerlean S, O' Connor P, Kennedy C
Department of Pharmacology, Trinity College Dublin School of Medicine, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland.
Department of General Practice, Health Sciences Centre, University College Dublin School of Medicine, Dublin, Ireland.
QJM. 2025 Mar 1;118(3):143-145. doi: 10.1093/qjmed/hcae144.
Hypercholesterolemia is a well-described risk factor for atherosclerotic cardiovascular disease. Statins remain the cornerstone of therapy. Statin intolerance (SI) particularly statin associated muscle symptoms (SAMS) and inappropriate stopping of treatment is associated with increased cardiovascular risk. A significant proportion of reported SAMS relates to expectation of side effects and can be termed the 'negative drucebo effect'. Patients should be educated about SI, the negative drucebo effect, in addition to the benefits of adherence to the therapy when first prescribed a statin. The aim of this commentary is to discuss the issue of SI, the negative drucebo effect and to suggest some interventions that may be used to address this issue.
高胆固醇血症是动脉粥样硬化性心血管疾病中一个广为人知的危险因素。他汀类药物仍然是治疗的基石。他汀不耐受（SI），尤其是他汀相关肌肉症状（SAMS）以及不适当的停药与心血管风险增加有关。报告的SAMS中有很大一部分与对副作用的预期有关，可称之为“负安慰剂效应”。当首次给患者开他汀类药物时，除了告知坚持治疗的益处外，还应让患者了解SI和负安慰剂效应。本评论的目的是讨论SI问题、负安慰剂效应，并提出一些可能用于解决该问题的干预措施。
